Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor

Journal for ImmunoTherapy of Cancer

Volumn 5, Issue 1, 2017, Pages

  Escandon, Julia ^a,b   Peacock, Stephanie ^a   Trabolsi, Asaad ^a   Thomas, David B ^c   Layka, Ayman ^a   Lutzky, Jose ^a,d  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d Mount Sinai Comprehensive Cancer Center   (United States)

Author keywords

Immune checkpoint inhibitor; Interstitial nephritis; Nivolumab; PD 1 ligand (PD L1); Pembrolizumab; Programed death 1 receptor (PD 1)

Indexed keywords

ATORVASTATIN; BUTALBITAL PLUS CAFFEINE PLUS PARACETAMOL; CLONIDINE; FENTANYL; FERROUS SULFATE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; IPILIMUMAB; LORAZEPAM; METHYLPREDNISOLONE; MONTELUKAST; NIFEDIPINE; NIVOLUMAB; OMEPRAZOLE; PEMBROLIZUMAB; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; TEMAZEPAM; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; ARTHRITIS; ARTICLE; BRAIN DAMAGE; CANCER REGRESSION; CASE REPORT; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; MALE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PSORIASIS; SENTINEL LYMPH NODE BIOPSY; ADVERSE DRUG REACTION; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; INFLAMMATION; MELANOMA; METASTASIS; PATHOLOGY;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; IMMUNOTHERAPY; INFLAMMATION; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; NEPHRITIS, INTERSTITIAL; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85010007266     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-016-0205-2     Document Type: Article

References (9)

1. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908-18.
2. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-30.
3. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375-84.
4. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23-34.
5. Pharmaceutical company. Opdivo [package insert]. Princeton: Bristol-Myers Squibb Company; 2016.
6. Pharmaceutical company. Keytruda [package insert]. Whitehouse Station: Merck & Co INC; 2015.
7. Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13(8):473-86.
8. Weber JS, Antonia SJ, Topalian SL, Schadendorf D, Larkin JM, Sznol M, Liu HY, Waxman I, Robert C. Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma(MEL): A pooled analysis. J Clin Oncol. 2015;(suppl; abstr 9018).
9. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med. 2013;2(5):662-73.